

Special Issue

Managing *Staphylococcus* spp. Infections: Current Practices and Future Directions

Message from the Guest Editor

Staphylococcus aureus is often associated with varied clinical diseases. *S. aureus* can cause a range of clinical manifestations. Coagulase-negative staphylococci (CNS), especially *S. epidermidis* and *S. haemolyticus*, although part of the normal skin flora, have emerged as opportunistic pathogens, particularly in immunocompromised patients and those with indwelling medical devices. *S. lugdunensis* has also emerged as a significant human pathogen, with distinct clinical and microbiological characteristics. Several pathogenic factors associated with staphylococcal infections have been identified, including biofilm formation and toxin and adhesin production. Treatment remains challenging due to the emergence of multidrug-resistant strains. With the escalation of antibiotic resistance globally, the need for novel therapies, such as biofilm-disrupting agents, bacteriophages, phage-encoded enzymes, nanoparticle-based delivery systems, and monoclonal antibodies, is more crucial than ever. This Special Issue focuses on current practices in managing staphylococcal infections, particularly focusing on novel approaches and future directions in the context of growing antibiotic resistance.

Guest Editor

Dr. Nikolaos Giormezis

Department of Microbiology, Medical School, University of Patras,
26504 Patras, Greece

Deadline for manuscript submissions

31 December 2026



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/243649

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)